Cansino Historical Income Statement
| 688185 Stock | 60.21 1.02 1.67% |
Historical analysis of Cansino Biologics income statement accounts such as Interest Income of 105.1 M, Interest Expense of 67.4 M or Selling General Administrative of 680.2 M can show how well Cansino Biologics performed in making a profits. Evaluating Cansino Biologics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cansino Biologics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cansino Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cansino Biologics is a good buy for the upcoming year.
Cansino |
About Cansino Income Statement Analysis
Cansino Biologics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cansino Biologics shareholders. The income statement also shows Cansino investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cansino Biologics Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cansino Biologics. It is also known as Cansino Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Cansino Biologics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cansino Biologics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Cansino Biologics' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 67.4 M, whereas Tax Provision is forecasted to decline to (12 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 79.7M | 65.9M | 100.1M | 105.1M | Net Interest Income | 59.0M | 24.1M | 35.7M | 27.1M |
Cansino Biologics income statement Correlations
Click cells to compare fundamentals
Cansino Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cansino Biologics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 21.8M | 31.6M | 59.0M | 24.1M | 35.7M | 27.1M | |
| Interest Income | 21.8M | 31.7M | 79.7M | 65.9M | 100.1M | 105.1M | |
| Interest Expense | 11.9M | 26.5M | 20.4M | 41.3M | 64.1M | 67.4M | |
| Selling General Administrative | 68.1M | 99.4M | 337.6M | 544.7M | 647.8M | 680.2M | |
| Total Revenue | 5.7M | 18.5M | 4.3B | 1.0B | 345.2M | 327.9M | |
| Gross Profit | 2.1M | 4.7M | 3.0B | (186.6M) | (876.0M) | (832.2M) | |
| Other Operating Expenses | 3.0M | 3.9M | 10.2M | 8.4M | 9.6M | 4.8M | |
| Operating Income | (204.2M) | (440.3M) | 1.8B | (1.4B) | (2.1B) | (2.0B) | |
| Net Income From Continuing Ops | (156.8M) | (396.6M) | 1.9B | (964.8M) | (2.0B) | (1.9B) | |
| Ebit | (217.9M) | (517.7M) | 1.8B | (1.5B) | (1.4B) | (1.3B) | |
| Research Development | 151.7M | 428.5M | 878.7M | 778.3M | 638.0M | 480.4M | |
| Ebitda | (134.3M) | (364.8M) | 2.0B | (946.3M) | (1.1B) | (1.0B) | |
| Cost Of Revenue | 147.5K | 13.8M | 1.3B | 1.2B | 1.2B | 617.7M | |
| Total Operating Expenses | 204.2M | 458.9M | 2.5B | 2.5B | 2.4B | 1.3B | |
| Reconciled Depreciation | 22.5M | 31.8M | 88.5M | 196.4M | 269.1M | 282.5M | |
| Income Before Tax | (156.8M) | (396.6M) | 1.9B | (1.2B) | (2.0B) | (1.9B) | |
| Net Income Applicable To Common Shares | (156.8M) | (396.6M) | 1.9B | (909.4M) | (1.0B) | (993.6M) | |
| Net Income | (156.8M) | (396.6M) | 1.9B | (909.4M) | (1.5B) | (1.4B) |
Currently Active Assets on Macroaxis
Other Information on Investing in Cansino Stock
Cansino Biologics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cansino Biologics shareholders. The income statement also shows Cansino investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).